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Abstract
Background: Despite strong laboratory evidence that non-steroidal anti-inflammatory drugs (NSAIDs) could prevent
prostate cancer, epidemiological studies have so far reported conflicting results. Most studies were limited by lack of
information on dosage and duration of use of the different classes of NSAIDs.
Methods: We conducted a nested case-control study using data from Saskatchewan Prescription Drug Plan (SPDP) and
Cancer Registry to examine the effects of dose and duration of use of five classes of NSAIDs on prostate cancer risk. Cases
(N=9,007) were men aged $40 years diagnosed with prostatic carcinoma between 1985 and 2000, and were matched to
four controls on age and duration of SPDP membership. Detailed histories of exposure to prescription NSAIDs and other
drugs were obtained from the SPDP.
Results: Any use of propionates (e.g., ibuprofen, naproxen) was associated with a modest reduction in prostate cancer risk
(Odds ratio=0.90; 95%CI 0.84-0.95), whereas use of other NSAIDs was not. In particular, we did not observe the
hypothesized inverse association with aspirin use (1.01; 0.95–1.07). There was no clear evidence of dose-response or
duration-response relationships for any of the examined NSAID classes.
Conclusions: Our findings suggest modest benefits of at least some NSAIDs in reducing prostate cancer risk.
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Introduction
It has been shown that non-steroidal anti-inflammatory drugs
(NSAIDs) could prevent the development of colon cancer [1], and
possibly other cancers [2,3] including prostate cancer [4].
Proposed mechanisms for these effects, including induction of
apoptosis [5] and inhibition of cellular proliferation and
angiogenesis [6], occur at least partly through the inhibition of
the cyclooxygenase (COX) enzymes involved in prostaglandin
synthesis. Over-expression of COX-2 has been observed in
prostate cancer cells [7], and higher levels of prostaglandins have
been detected in malignant compared to benign prostate tissues
[8]. In all 12 animal studies included in a recent review, NSAIDs
exhibited inhibitory effects on prostate cancer development and
progression to invasive disease [9].
Despite strong laboratory evidence, epidemiological studies of
NSAID use and prostate cancer have so far produced conflicting
results [4,10,11]. Although most studies reported inverse associations
between aspirin use and prostate cancer occurrence, some found
positive [12] or no associations [13,14,15,16]. Studies that examined
the effect of aspirin use on the occurrence of advanced prostate
cancer were more consistent [12,13,14,17,18,19]. Studies that
examined the effects of non-aspirin (NA-NSAIDs) were inconsistent
withcohortstudiesgenerallyshowingnoassociationandcase-control
studies suggesting statistically significant inverse associations [4].
Most reviewed studies were limited by exposure and disease
misclassification, by limited information on dose and duration of
use and by the possibility of screening and other biases [4]. Also,
there have been no studies that assessed the effects of individual
classes of NSAIDs.
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chemical classes of NSAIDs on prostate cancer risk using a
nested case-control analysis of a historical cohort that was
assembled by means of record linkage of several large
longitudinal databases of routinely collected health data from
the Canadian province of Saskatchewan. To our knowledge,
this is the largest study to specifically examine the hypothesis
that NSAIDs may reduce the risk of prostate cancer, and the
first study in the field to systematically examine the effects of
five different classes of NSAIDs on prostate cancer risk,
rather than just examine the effects of all NSAIDs or one
NSAID.
Methods
Ethics statement
This study was approved by the Ethics Review Boards of
McGill University and the University of Saskatchewan. Both
boards deemed that obtaining consent from individual partici-
pants was not necessary or feasible because this study was
based on the analysis of anonymous records obtained from
administrative databases that include information on all residents
of Saskatchewan.
Data sources
Data were obtained by linkage of Saskatchewan Ministry of
Health (SH) databases and the Saskatchewan Cancer Registry
(SCR). SH provides publicly funded health insurance coverage,
including coverage for prescription drugs and hospital and
physician services, to most of the province’s one million residents.
Eligibility for coverage is not based on age or income [20]. For
administrative purposes, SH maintains several centralized elec-
tronic databases that can be linked using a unique health services
number.
The Saskatchewan Prescription Drug Plan (SPDP), in operation
since 1975, records all pharmacy claims for formulary drugs
dispensed to Saskatchewan beneficiaries [20]. The accuracy of the
recorded prescription information is high [21]. However, the
SPDP lacks information on drugs given during hospitalization or
bought over the counter (OTC).
All cancers occurring in the study cohort were identified using
the population-based SCR, in operation since 1932. Because
reporting of cancer cases is mandated by law, cancer registration is
virtually complete in Saskatchewan [22]. Most (97%) cases are
pathologically-confirmed, and fewer than 3% of registrations
originate from death certificates [22]. For the cases, we also had
access to detailed clinical information, including stage, Gleason
score and results of PSA testing, which was obtained by abstracting
clinical charts of all included prostate cancer cases as part of
another research project. The methods of that project are
documented in detail elsewhere [23].
Information on comorbidity and indication of NSAID use (e.g.,
diabetes, ischemic heart disease, arthritis, and prostatitis) and on
utilization of health care services including urological procedures
(Table 1) was obtained from SH hospital separation and
physician services databases which, since 1971, recorded most
services provided by Saskatchewan hospitals and physicians. The
collected data include diagnostic and treatment information
including a primary diagnosis, coded using the International
Classification of Diseases, Ninth Revision (ICD-9), and service or
procedure codes [20]. We used several previously validated
algorithms [24] to identify cases of chronic diseases in our cohort
(Table 1).
Historical cohort
The study cohort consisted of all men aged 40 years or older
who were registered with SH during 1985–2000. Cohort members
were followed from the latest of the study start date (January 1,
1985), their 40th birthday or the date of immigration to
Saskatchewan until the study end date (December 31, 2000), or
the date of diagnosis of prostate cancer, death or emigration,
whichever occurred first. The population registry of SH, which
tracks eligibility for health insurance coverage [20], was used to
determine cohort members’ vital and migration status.
Definition of cases and controls
To be eligible for inclusion in the nested case-control analysis, a
participant must have been (1) free of cancer (except non-
melanoma skin cancer) before the index date, defined as the date of
diagnosis for a case or the date of diagnosis of the matching case
for a control; and (2) a beneficiary of prescription drug coverage
for a minimum of 5 years prior to his index date (to ensure that all
participants had a reasonable opportunity to fill NSAID
prescriptions before the index date). Registered Indians and other
federal beneficiaries (9% of the population) were excluded because
information about their drug use is not captured in the SPDP [20].
The cases group included all men (N=9,007) in the study
cohort who had a diagnosis of primary prostatic carcinoma (ICD-
Oncology code C61; morphology codes: 8140/3, 8010/3, and
8000/3). Using incidence density sampling [25], we randomly
selected up to four controls (N=35,891) for each case from among
eligible cohort members, matched on age (61 year) and duration
of SPDP membership.
Measurement of prescription drug use
For each participant, detailed histories of exposure to dispensed
NSAIDs and 18 other drug classes were obtained from the
SPDP for the period between January 1, 1976, or the coverage
initiation date, whichever was later, and the index date. The
length of these histories was $10 years in 98.5% of participants
(median 19, range 5–27). The WHO Anatomic Therapeutic
Chemical (ATC) classification [26] was used to classify drugs, e.g.,
NSAIDs were defined as all drugs in the Saskatchewan drug
formulary with ATC codes M01A* or N02BA*. NSAIDs were
further classified into seven different chemical classes (Table 1). To
facilitate comparisons with previous studies, NSAIDs were also
classified, in separate analyses, into aspirin and non-aspirin
NSAIDs (NA-NSAIDs).
Exposure to each class of NSAIDs was characterized in two
ways: (1) as a binary (‘‘any use’’) variable indicating whether a
participant ever filled a prescription of any drug in the index class
at any time during his exposure history. (2) As an ordinal variable
representing the quintiles of the average annual dose of the index
class calculated by dividing the total dispensed quantity of the class
by its overall duration of use (measured from the dispensing date of
the first prescription that included a drug in that class). All drug
use in the year immediately prior to the index date was excluded to
avoid protopathic bias [27].
Because different drugs in the same class may have different
pharmacologic potency, the total dispensed quantity for each drug
was expressed as a proportion of the WHO’s defined daily dose
(DDD) for that drug before summing up all these proportions as
the total dispensed quantity of the class (see Table 1 for list of
DDDs). The DDD is ‘‘the assumed average maintenance dose per
day for a drug used for its main indication in adults’’ [26]. In most
analyses, the average annual dose was categorized using the
quintiles of the distribution, which were calculated after excluding
observations with zero annual dose (‘‘non-users’’). Therefore, this
NSAIDS and Prostate Cancer Risk
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cutoff points and a reference category formed by non-users.
We did not have information on the daily dose or duration of
treatment as recommended by the prescribing clinician. To
measure the duration of use, we relied on the fact that for most
regular NSAID users, prescriptions were typically filled every 3
months. So for every participant, we divided the exposure history
into 3-month periods beginning at the date of first prescription
filled by that participant. We then counted the number of such
periods that included at least 1 prescription. The duration of use
variable (in years) was then computed as the sum of these 3-month
periods, and further categorized into 7 categories: 0, 0.25, 0.5,
0.75–1.5, 1.75–3.0, 3.25–6.0 and $6.25 years, with cutoff points
corresponding to the 50
th,7 5
th,9 0
th,9 5
th,9 9
th centiles of the
duration of aspirin use variable.
Statistical analysis
We used conditional logistic regression (CLR) to model the
effects of NSAID use on prostate cancer risk while accounting for
matching and other confounding variables. The final models were
adjusted for screening predictors and, when appropriate, for use of
other classes of NSAIDs.
We lacked information on PSA testing among the controls; so
instead we adjusted for three variables believed to be associated with
heightened screening [28]: ever having seen a urologist in the 1–11
years prior to the index date (i.e. excluding the year immediately prior
to the index date); volume of family physician visits in the 5 years prior
to the index date; and a composite binary variable (SCREENED)
which took the value of 1 if a participant was diagnosed with a
prostatic condition other than prostate cancer or received a diagnostic
or therapeutic intervention for such a condition (see Table 1 for
Table 1. Definitions of variables used in the analysis.
Variable Definition
NSAID classes
a
Arylacetic acids Diclofenac (100), Etodolac (400), Indomethacin (100), Sulindac (400), Tolmetin (700), Zomepirac (300)
Butylpyrazolidines Phenylbutazone (300)
Fenamates Floctafenine (1000), Mefenamic Acid (1000)
Oxicams Meloxicam (15), Piroxicam (20)
Propionates Fenoprofen (1200), Flurbiprofen (200), Ibuprofen (1200), Ketoprofen (150), Nabumetone (1000), Naproxen (500)
Coxibs Celecoxib (200), Rofecoxib (20)
Aspirin (3000)
Screening
SCREENED Binary variable with 1 indicating whether at any point prior to the index date a subject had a physician visit for BPH (ICD-9 code
600.*), prostatitis (601.*) or ‘‘other disorders of prostate’’ (602.*); or any point during the 11 years prior to the index date, a
subject received at least one prescription for finasteride or an a-blocker or had prostatic ablation or resection, or testing of
prostatic secretions. We assumed the men who received these services had at least a DRE.
Medical conditions
b
Diabetes $2 physician claims with ICD-9=250
Hypertension $2 physician claims with ICD-9=401, 405 OR $2 prescriptions for selective b-blockers; thiazides; CCBs-DH; or centrally acting
anti-adrenergics
Rheumatoid arthritis $2 physician claims with ICD-9=714 OR $2 prescriptions for DMRDs or steroids
Osteoarthritis $3 physician claims with ICD-9=710–713; 715–739; No DMRD or steroids
Other inflammatory arthritis $3 physician claims with ICD-9=710–713; 715–739 AND $1 DMRD or steroids
Cardiac disease/stroke $3 physician claims with ICD-9=390–400;402–404;406–459
GI bleeding $1 physician claims with ICD-9=578
Prostatic hypertrophy $1 physician claims with ICD-9=600 OR $1 prescriptions for finasteride or a-blockers OR $1 TURP or ablation
Prostatitis $1 physician claims with ICD-9=601 OR $1 physician claims for MEPS.
Others
Income status Binary variable with 1 indicating ever having a prescription flagged for receiving income security benefits.
Vasectomy, TURP, Prostatic
biopsy, MEPS
Information on these procedures was extracted from a list of all physician-provided urological services (services for which a
physician claimed a fee-for-service code under section R of the Saskatchewan Ministry of Health’s ‘‘Payment Schedule for
Insured Services Provided by a Physician’’) since January 1, 1975.
Classes of medications Prostatism agents, androgen antagonists, Lipid lowering agents, Angiotensin converting enzyme inhibitors, Angiotensin receptor
blockers, a-a n db-blockers, Antihypertensive calcium channel blockers, Centrally acting antihypertensives, Vasodilators, Diuretics,
DMRDs, Systemic steroids, Anticoagulants, Cardiac glycosides, Proton pump inhibitors, H2 receptor antagonists, Other
ulcer-healing agents. All drugs were classified according to the WHO ATC classification (see text).
a) For each NSAID, the WHO’s defined daily dose (DDD) used in the analysis is listed in parenthesis (in milligrams). The DDD is ‘‘the assumed average maintenance dose
per day for a drug used for its main indication in adults’’(WHO Collaborating Centre for Drug Statistics Methodology, 2002). Using DDDs, we effectively weighted the
prescribed quantity of each NSAID by its anti-inflammatory potency.
b) Based on the most valid chronic disease identification algorithms (those algorithms with the highest Kappa and Youden’s index values) from a comprehensive review
of the literature performed by Lix et al (20).
BPH: Benign prostate hypertrophy; CCBs-DH: Calcium channel blockers, dihydropyridine; DMRD: Disease-modifying anti-rheumatic drugs; DRE: Digital rectal
examination; GI: Gastro-intestinal; MEPS: Microscopic examination of prostatic secretions; TURP: Transurethral resection of prostate.
doi:10.1371/journal.pone.0016412.t001
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variables were associated with increased detection of early prostate
cancers and reduced detection of advanced prostate cancers.
We also performed a forward step-wise empirical search for
confounders. A variable was considered a confounder if its inclusion
inadjustedmodels resulted ina.2%changeinOR estimates of any
of the study’s main exposures. Using this criterion, none of the
variables considered, including a large number of medications (e.g.,
finasteride, statins) and indications of NSAID use (see Table 1 for a
list of these variables), was deemed an empirical confounder, and
were therefore excluded from the final models.
We used incremental odds ratios (iORs) to assess for monotonic
linear dose-response relationships between the quintiles of the
average annual dose and prostate cancer risk. Unlike conventional
ORs which contrast the risk at each exposure level with the same
reference category, iORs are derived using models that contrast
the effect at each level with that at the previous level [29].
Therefore, iORs consistently (at all levels) above (or below) 1.0
suggest a monotonic increasing (or decreasing) dose-response
relationship. The confidence intervals around these iORs provide
a measure of the statistical significance of these trends.
Given the long exposure histories in this cohort, the NSAID
users group will naturally include participants with highly variable
exposure histories. To reduce the effect of this heterogeneity, and
to assess for the presence of an ‘‘induction period’’ for NSAID
effects (the time interval between an exposure exerting its causal
effects and disease initiation or prevention [30]), analyses were
repeated after dividing the exposure history into six successive
periods: the first spanned the 12-month period prior to the index
date. The other periods spanned 5 years each and were as follows:
1.1–6, 6.1–11, 11.1–16, 16.1–21, 21.1–26 years. A separate
exposure index was computed for each period by limiting exposure
measurements to prescriptions dispensed during that period [31].
As before, CLR models were used to estimates ORs associated
with drug use in each period with mutual adjustment for exposure
in other periods as well as adjustment for screening predictors.
Results
Most (80%) cases were older than 65 (median age =73), and
were mostly (83%) diagnosed during the 1990s, following the
widespread use of PSA screening. At diagnosis, 12% of cases had
Table 2. Ever-use of NSAIDs and descriptive statistics of total number of prescriptions among ever-users by case-control status
and drug category.
Drug categorya No (%) of ever-users No. of prescriptions among ever-users
Mean SD Q1 Median Q3 Max
Aspirin
Controls 17469(48.7) 6.5 13.0 1.0 2.0 5.0 238.0
Cases 4653(51.7) 6.6 13.6 1.0 2.0 5.0 172.0
Coxibs
Controls 100(0.3) 3.4 3.0 1.0 2.0 5.0 14.0
Cases 27(0.3) 3.1 2.2 1.0 3.0 4.0 9.0
Arylacetic acids
Controls 16779(46.7) 7.3 14.2 1.0 3.0 6.0 283.0
Cases 4442(49.3) 7.1 13.2 1.0 3.0 6.0 141.0
Butylpyrazolidines
Controls 6102(17.0) 2.6 4.6 1.0 1.0 2.0 122.0
Cases 1657(18.4) 2.6 4.1 1.0 1.0 2.0 81.0
Fenamates
Controls 833(2.3) 2.5 7.5 1.0 1.0 2.0 95.0
Cases 234(2.6) 1.9 3.3 1.0 1.0 2.0 43.0
Oxicams
Controls 5976(16.7) 4.9 9.1 1.0 2.0 4.0 164.0
Cases 1620(18.0) 5.0 9.2 1.0 2.0 4.0 100.0
Propionates
Controls 18667(52.0) 6.4 12.3 1.0 2.0 6.0 208.0
Cases 4881(54.2) 6.1 11.1 1.0 2.0 6.0 151.0
NA-NSAIDs
Controls 25542(71.2) 11.3 19.8 2.0 4.0 11.0 330.0
Cases 6683(74.2) 11.1 18.2 2.0 4.0 11.0 216.0
NSAIDs
Controls 28516(79.5) 14.2 23.5 2.0 6.0 15.0 372.0
Cases 7406(82.2) 14.2 22.5 2.0 6.0 15.0 295.0
a) See Table 1 for a list of drugs in each category.
SD: standard deviation; Q1 and Q3: First and third quartiles.
doi:10.1371/journal.pone.0016412.t002
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15% had metastases (stage D). Gleason score was greater than 7 in
14% of cases.
Overall, 82.2% of cases and 79.5% of controls have received at
least one NSAID prescription (Table 2). Propionates, arylacetic
acids and aspirin were the most commonly prescribed NSAIDs.
Ignoring matching, there were no significant differences between
cases and controls in the median number of filled prescriptions for
any of the examined classes (Table 2).
In models accounting for matching but not adjusting for any
other confounders (Table 3, left panel), ever filling an NSAID
prescription was associated with a small increase in risk (odds ratio
[OR]=1.21; 95%CI 1.13–1.28). Similar results were observed for
the different classes of NSAIDs, including aspirin (1.13; 1.08–1.18)
and propionates (1.10; 1.05–1.15).
Following adjustment for screening and aspirin use (Table 3,
right panel), any use of NA-NSAIDs was inversely associated with
prostate cancer risk (0.88; 0.82–0.94). In a model with mutual
adjustment for 5 NSAID classes, propionates (0.89; 0.84–0.95) and
arylacetic acids (0.94; 0.88–1.00) were inversely associated with
disease risk whereas any use of aspirin was not (OR=1.01
[95%0.95–1.07]).
A similar pattern was observed when exposure was represented
as the quintiles of the average annual dose. Table 4 shows the
results from two separate models that included mutual adjustment
for quintiles of the average annual dose of five NSAID classes. In
one model, dose quintiles were entered as an ordinal variable (a
linear term). In the second, each level of the ordinal dose variable
was represented in the model with a binary indicator variable. The
OR associated with the linear term of aspirin annual dose was 0.99
(0.97–1.01). Aspirin use was not statistically significantly associated
with prostate cancer at any dose level. On the other hand,
propionate use was inversely associated with prostate cancer risk;
linear term=0.97 (0.96–0.99). Inverse associations were seen at all
levels above 1.1 DDDs/year, but there was no clear evidence of a
monotonic dose-effect relationship.
Similar results (data not shown) were obtained when the average
annual dose variables were categorized using ‘‘fixed’’ cutoff points
that were all multiples of 10 DDDs/year, (i.e., 2.5, 5, 10, 20 and
40; 10 DDDs/year of NSAID use is equivalent to 1 year use of a
once daily dose of 81 milligrams of aspirin). Specifically, for each
NSAID class, the annual average dose was categorized into 0
(never-use), 0.1–2.4, 2.5–4.9, 5.0–9.9, 10.0–19.9, 20.0–39.9 and
40.0–79.9 DDDs/year. In these analyses, inverse associations at all
levels were observed for propionates. However, there was no clear
monotonic dose-effect relationship demonstrated in any of these
analyses.
As shown in Table 5, duration of use of aspirin was not
associated with prostate cancer risk (linear term OR=0.99
[0.97–1.02]). Although all levels of the propionate duration of use
variable were inversely associated with disease risk, the
associations were generally not statistically significant, and there
was no clear trend of stronger associations with longer duration
of use.
Table 6 shows results of models that included period-specific
binary terms for ever-use of each of five classes of NSAIDs. The
aim of these analyses was to identify the exposure window (period)
that is most likely associated with possible biological effects of
NSAID use. The strongest inverse association for aspirin was seen
for the period 1.1-6 years before the index date, but there was no
discernable pattern to the period-specific ORs, and none of them
was statistically significant. For propionates, the strongest inverse
association was observed during the 11.1–16 years period,
OR=0.85 (95%CI 0.76–0.94). Strong positive associations were
observed for several NSAIDs during the one-year period
immediately before the index date, likely due to protopathic bias
as NSAIDs are widely used to manage pain, which could be a
symptom of undetected cancer. Similar pattern of results was
observed when the linear (ordinal) term of the average annual dose
(as defined in the dose-effect analysis) was substituted for the
binary ever-use term (data not shown).
Discussion
We found that propionate use was consistently inversely related
to prostate cancer risk whereas aspirin use was not. The strongest
association was observed with propionate use taking place 11–16
years before diagnosis.
Although the bulk of the literature is suggestive of protective
effects for aspirin use [4], our results are consistent with those from
four large population-based cohort studies [13,14,15,16] in
Table 3. Effect of ever filling a prescription of an NSAID class on the risk of developing prostate cancer.
Variable Unadjusted OR
a (95%CI) P-value Adjusted OR
b (95%CI) P-value
Aspirin 1.13 (1.08–1.18) ,0.001 1.01 (0.95–1.07) 0.816
Arylacetic acids 1.11 (1.06–1.17) ,0.001 0.94 (0.88–1.00) 0.043
Butylpyrazolidines 1.10 (1.04–1.17) 0.002 0.99 (0.92–1.07) 0.776
Oxicams 1.10 (1.03–1.17) 0.002 0.96 (0.89–1.04) 0.368
Propionates 1.10 (1.05–1.15) ,0.001 0.89 (0.84–0.95) ,0.001
Coxibs 1.09 (0.70–1.69) 0.712 Excluded
c
Fenamates 1.12 (0.97–1.30) 0.119 Excluded
c
NA-NSAIDs 1.17 (1.11–1.24) ,0.001 0.88 (0.82–0.94)
d ,0.001
NSAIDs 1.21 (1.13–1.28) ,0.001 0.87 (0.80–0.94) ,0.001
a) ORs from unadjusted conditional logistic regression models for comparison.
b) Adjusted for ever visited a urologist 1–11 years prior, SCREENED and volume of family physician visits in the 5 years prior to the index date and, when appropriate, for
use of other NSAID classes.
c) Fenamates and Coxibs were excluded from this model because of small numbers.
d) From an adjusted model that included terms for NA-NSAIDs and aspirin in addition to screening predictors as above.
Note: Effect estimates throughout the paper have been rounded to two decimal digits. This is not meant to imply that our results are accurate to two decimal digits
(most certainly they are not). However, rounding to one single digit would have made it difficult to spot any trends in the data.
doi:10.1371/journal.pone.0016412.t003
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developing prostate cancer.
Variable
a OR (95%CI)
b P-value iOR
c (95%CI) P-value
Aspirin
Linear term 0.99 (0.98–1.01) 0.380
Quintiles
Never-users 1.0 (reference)
0.1–0.1 1.04 (0.94–1.16) 0.422 1.04 (0.94–1.16) 0.422
0.2–0.6 1.08 (0.97–1.19) 0.146 1.03 (0.91–1.18) 0.617
0.7–1.7 0.97 (0.87–1.07) 0.547 0.90 (0.79–1.02) 0.102
1.8–4.9 1.02 (0.92–1.13) 0.734 1.05 (0.92–1.19) 0.448
$5.0 0.93 (0.84–1.03) 0.158 0.91 (0.80–1.03) 0.147
Arylacetic acids
Linear term 0.99 (0.97–1.01) 0.292
Quintiles
Never-users 1.0 (reference)
0.1–1.0 0.94 (0.85–1.05) 0.290 0.94 (0.85–1.05) 0.290
1.1–2.2 0.91 (0.82–1.01) 0.073 0.96 (0.84–1.10) 0.573
2.3–4.6 0.95 (0.86–1.05) 0.321 1.04 (0.92–1.19) 0.526
4.7–12.3 0.94 (0.85–1.05) 0.284 0.99 (0.87–1.13) 0.927
$12.4 0.97 (0.87–1.09) 0.615 1.03 (0.90–1.17) 0.648
Butylpyrazolidines
Linear term 1.00 (0.98–1.02) 0.932
Quintiles
Never-users 1.0 (reference)
0.1–0.5 0.99 (0.85–1.16) 0.929 0.99 (0.85–1.16) 0.929
0.6–0.8 1.03 (0.88–1.20) 0.751 1.03 (0.83–1.28) 0.767
0.9–1.5 0.98 (0.84–1.14) 0.782 0.95 (0.77–1.18) 0.667
1.6–3.0 0.86 (0.74–1.01) 0.070 0.88 (0.71–1.10) 0.263
$3.1 1.11 (0.95–1.30) 0.197 1.28 (1.04–1.59) 0.023
Oxicams
Linear term 0.99 (0.96–1.01) 0.254
Quintiles
Never-users 1.0 (reference)
0.1–1.4 1.06 (0.90–1.23) 0.491 1.06 (0.90–1.23) 0.491
1.5–2.4 0.97 (0.83–1.14) 0.699 0.92 (0.74–1.14) 0.439
2.5–4.4 0.99 (0.85–1.16) 0.929 1.02 (0.82–1.27) 0.825
4.5–10.6 0.88 (0.75–1.03) 0.120 0.89 (0.72–1.10) 0.280
$10.7 0.95 (0.81–1.11) 0.516 1.07 (0.87–1.33) 0.504
Propionates
Linear term 0.97 (0.96–0.99) 0.004
Quintiles
Never-users 1.0 (reference)
0.1–1.1 0.92 (0.83–1.01) 0.092 0.92 (0.83–1.01) 0.092
1.2–2.5 0.88 (0.80–0.98) 0.017 0.97 (0.85–1.10) 0.588
2.6–5.1 0.91 (0.82–1.01) 0.072 1.03 (0.91–1.17) 0.641
5.2–13.2 0.88 (0.79–0.97) 0.012 0.96 (0.85–1.09) 0.543
$13.3 0.89 (0.80–1.00) 0.042 1.02 (0.90–1.16) 0.757
a) For each class, results from two separate models are reported. In one model, the dose quintiles were entered as an ordinal variable (a linear term). In the second
model, each level (quintile) of the ordinal dose variable was represented in the model with a binary indicator variable. In the analyses shown in the left panel, the
reference group is men who did not fill any prescriptions of the index class (never-users).
b) Adjusted for ever having visited a urologist 1–11 years prior, SCREENED and volume of family physician visits in the 5 years prior to the index date, and for all NSAID
classes listed in the table.
c) iOR: Incremental OR. The ORs in the right panel are incremental ORs from models that contrast the effect at each level with that at the previous level. iORs consistently
(at all levels) above (or below) 1.0 suggest a monotonic increasing (or decreasing) dose-response relationship.
doi:10.1371/journal.pone.0016412.t004
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Variable
a OR (95%CI)
b P-value iOR
c (95%CI) P-value
Aspirin
Linear term 0.99 (0.97–1.02) 0.594
Categories
Never-users 1.0 (reference)
0.25 1.03 (0.96–1.12) 0.381 1.03 (0.96–1.12) 0.381
0.5 1.14 (1.03–1.26) 0.014 1.10 (0.98–1.23) 0.097
0.75–1.5 0.96 (0.87–1.06) 0.400 0.84 (0.74–0.95) 0.007
1.75–3.0 0.87 (0.75–1.01) 0.059 0.91 (0.77–1.06) 0.233
3.25–6.0 0.91 (0.77–1.07) 0.262 1.05 (0.85–1.29) 0.668
.6.0 1.26 (1.00–1.57) 0.047 1.38 (1.06–1.81) 0.018
Arylacetic acids
Linear term 1.00 (0.97–1.02) 0.656
Categories
Never-users 1.0 (reference)
0.25 0.92 (0.85–1.00) 0.057 0.92 (0.85–1.00) 0.057
0.5 0.97 (0.87–1.08) 0.577 1.05 (0.94–1.18) 0.402
0.75–1.5 0.96 (0.88–1.06) 0.428 0.99 (0.88–1.12) 0.897
1.75–3.0 1.02 (0.89–1.17) 0.801 1.06 (0.91–1.22) 0.452
3.25–6.0 0.91 (0.77–1.08) 0.295 0.89 (0.73–1.10) 0.281
.6.0 1.03 (0.82–1.30) 0.789 1.13 (0.86–1.48) 0.368
Butylpyrazolidines
Linear term 0.99 (0.95–1.03) 0.660
Categories
Never-users 1.0 (reference)
0.25 0.99 (0.90–1.09) 0.888 0.99 (0.90–1.09) 0.888
0.5 0.92 (0.78–1.08) 0.315 0.93 (0.77–1.11) 0.403
0.75–1.5 0.94 (0.79–1.13) 0.517 1.03 (0.81–1.30) 0.837
1.75–3.0 1.41 (0.99–2.02) 0.058 1.50 (1.01–2.23) 0.044
3.25–6.0 0.85 (0.46–1.56) 0.601 0.60 (0.30–1.21) 0.156
.6.0 0.29 (0.06–1.37) 0.118 0.34 (0.06–1.81) 0.204
Oxicams
Linear term 0.97 (0.94–1.01) 0.099
Categories
Never-users 1.0 (reference)
0.25 1.02 (0.92–1.13) 0.686 1.02 (0.92–1.13) 0.686
0.5 0.92 (0.78–1.08) 0.283 0.90 (0.75–1.08) 0.241
0.75–1.5 0.85 (0.72–0.99) 0.035 0.92 (0.74–1.14) 0.467
1.75–3.0 0.92 (0.72–1.18) 0.525 1.09 (0.82–1.45) 0.547
3.25–6.0 1.04 (0.73–1.48) 0.817 1.13 (0.74–1.73) 0.575
.6.0 0.76 (0.36–1.60) 0.468 0.73 (0.32–1.65) 0.448
Propionates
Linear term 0.98 (0.96-1.00) 0.029
Categories
Never-users 1.0 (reference)
0.25 0.91 (0.84–0.99) 0.024 0.91 (0.84–0.99) 0.024
0.5 0.96 (0.87–1.07) 0.483 1.06 (0.95–1.18) 0.301
0.75–1.5 0.88 (0.80–0.96) 0.005 0.91 (0.81–1.02) 0.099
1.75–3.0 0.92 (0.80–1.06) 0.235 1.05 (0.91–1.21) 0.509
3.25–6.0 0.93 (0.78–1.11) 0.444 1.01 (0.83–1.24) 0.891
.6.0 0.87 (0.68–1.13) 0.298 0.94 (0.70–1.26) 0.662
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small aspirin-propionate difference was noted. Harris et al.
reviewed the evidence for the effect of NSAID use on 10 cancer
sites, and concluded that compared to aspirin and other NSAIDs,
ibuprofen (a propionate) has a stronger anti-cancer effect [32].
Very few studies have specifically examined the effects of
propionate use on prostate cancer [13,33], and their findings
were generally consistent with ours.
The lack of inverse association with aspirin use may have
been due to disease misclassification. Under-ascertainment of
cases could occur if some cancer cases were not captured by the
SCR or if occult prostate cancer, common among older men
[34], was under-detected. The errors are likely non-differential
with respect to NSAID use, and could bias our ORs towards the
null [35].
However, differential misclassification due to screening is likely
a more significant concern. NSAID users are more likely to be
screened, probably because of more frequent contacts with health
care providers [28,36]. One major limitation of SH databases is
the lack of information on PSA testing. As a workaround, we used
several predictors of screening to adjust our models for the effect of
screening [35]. These adjustments resulted in the expected
(downward) correction in the crude estimates. However, it is
possible that these predictors may have been misclassified with
respect to the participants’ true screening status. However, disease
misclassification does not explain the observed inverse association
with propionate use.
Errors in the measurement of NSAID use are another concern.
We assumed that the amount of NSAIDs dispensed is a good
approximation of actual consumption, which is likely true for
chronic users with repeated refills. We also lacked information on
non-prescription use, e.g., medications bought over the counter.
However, except for aspirin and ibuprofen, the non-prescribed
amounts are probably very small compared to the amounts of
prescribed medications [37].
Several lines of evidence suggest that misclassification due to
lack of information on OTC aspirin and ibuprofen use did not
lead to significant bias. There was no change in risk estimates for
ibuprofen use when we limited the analysis to cases diagnosed
before August 1989, the year when ibuprofen became available
without prescription in Saskatchewan. Similarly, ORs for aspirin
use did not change appreciably when we stratified the analysis by
markers of OTC aspirin use such as history of ischemic heart
disease and diabetes. Also, any such bias is likely non-differential.
So it could have biased the ORs towards the null, but that would
not explain the inverse associations observed for propionates
(including ibuprofen) use.
In addition, we used a Monte Carlo sensitivity analysis to assess
the potential effects of exposure measurement errors on study
estimates. Using multiple imputation and simulation methods,
levels of aspirin and ibuprofen use were adjusted to reflect both
random and systematic sources of underascertainment of their use
[38]. Regardless of NSAID type, exposure index or the assumed
a) For each class, results from two separate models are reported. In one model, the duration of use categories were entered as an ordinal variable (a linear term). In the
second model, each level of the ordinal duration of use variable was represented in the model with a binary indicator variable. In the analyses shown in the left panel,
the reference group is men who did not fill any prescriptions of the index class (never-users).
b) Adjusted for ever having visited a urologist 1–11 years prior, SCREENED and volume of family physician visits in the 5 years prior to the index date, and for all NSAID
classes listed in the table.
c) iOR: Incremental OR.
doi:10.1371/journal.pone.0016412.t005
Table 5. Cont.
Table 6. Effect of NSAID ever-use in each exposure period (in
years before the index date) on the risk of developing total
prostate cancer by NSAID category.
Variable OR (95%CI)
a P-value
Aspirin
#1 1.00 (0.87–1.16) 0.954
1.1–6 0.93 (0.83–1.03) 0.157
6.1–11 0.96 (0.87–1.06) 0.409
11.1–16 1.02 (0.91–1.15) 0.677
16.1–21 1.10 (0.96–1.27) 0.161
21.1–26 1.00 (0.79–1.26) 0.990
Arylacetic acids
#1 1.20 (1.06–1.37) 0.005
1.1–6 0.99 (0.91–1.08) 0.796
6.1–11 0.99 (0.90–1.09) 0.813
11.1–16 0.94 (0.84–1.05) 0.277
16.1–21 0.96 (0.83–1.12) 0.642
21.1–26 0.77 (0.57–1.05) 0.098
Butylpyrazolidines
#1 1.35 (0.45–4.05) 0.589
1.1–6 1.25 (0.89–1.76) 0.200
6.1–11 1.13 (0.91–1.41) 0.262
11.1–16 0.79 (0.65–0.97) 0.022
16.1–21 0.99 (0.80–1.23) 0.931
21.1–26 1.05 (0.78–1.42) 0.734
Oxicams
#1 0.90 (0.61–1.31) 0.567
1.1–6 0.96 (0.81–1.15) 0.683
6.1–11 1.01 (0.87–1.18) 0.886
11.1–16 0.96 (0.81–1.14) 0.674
16.1–21 0.84 (0.63–1.12) 0.234
Propionates
#1 1.11 (0.96–1.30) 0.164
1.1–6 0.93 (0.85–1.01) 0.098
6.1–11 0.96 (0.88–1.05) 0.426
11.1–16 0.85 (0.76–0.94) 0.001
16.1–21 1.05 (0.92–1.20) 0.439
21.1–26 0.87 (0.68–1.12) 0.291
a) Adjusted for ever visited a urologist 1–11 years prior, SCREENED and volume
of family physician visits in the 5 years prior to the index date, and to all terms
listed in the table.
doi:10.1371/journal.pone.0016412.t006
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estimates (data available on request). For propionates, all levels of
the average annual dose quintile variable remained inversely
related to prostate cancer risk, especially with higher simulated use
rates. For both aspirin and propionates, the linear trends were
smoother than those observed empirically.
The possibility of confounding should also be considered. We
found no evidence that any of a large number of medications and
indications and contraindications of NSAID use (Table 1) was a
significant confounder. We could not adjust for ethnicity.
However, the generation of men included in this study was
predominately Caucasian (most Aboriginal men were excluded),
thus any confounding effect is likely small [39]. We have no reason
to believe that family history of prostate cancer could be a
confounder. We lacked information on putative lifestyle risk
factors. In previous studies, adjustment for these factors did not
appreciably change the crude estimates [13,19,40]. This is not
surprising given the lack of known significant exogenous risk
factors for prostate cancer [41]. Although we cannot rule out the
possibility of bias due to residual confounding, our sensitivity
analyses suggest that even a strong confounder (one associated
with a 5-fold increase or decrease in prostate cancer risk) will not
fully explain the observed differences between aspirin and
propionate use.
The aspirin-propionate differences may also stem from
differences in patterns of use of these medications. Among older
men, aspirin is prescribed in low doses primarily for cardio-
protection whereas propionates are used in full strength doses
as analgesic and anti-inflammatory medications. However, our
dose-response analysis suggests that propionate use was inversely
related to prostate cancer risk at all dose levels whereas aspirin
was not.
Finally, the observed differences between aspirin and propio-
nates could be due to genuine heterogeneity in effect reflecting
differences in their pharmacokinetics or biological effects. For
instance, compared to other NSAIDs, aspirin undergoes an
extensive first pass hepatic metabolism following oral administra-
tion [19], which may translate into lower availability at the tissue
level inside the prostate gland. Aspirin is a potent inhibitor of
COX-1 whereas the propionates are potent inhibitors of both
COX-1 and COX-2 [42]. This is important because the bulk of
the evidence from laboratory studies is consistent with a more
important role for COX-2 in prostatic carcinogenesis [7,43].
Lastly, it has been suggested that some NSAIDs may have anti-
tumour effects independent of COX blockade [44]. For instance,
R-flurbiprofen and exisulind, NSAIDs that are not active against
COX, have significant anti-neoplastic properties [45]. Also, some
anti-tumour effects of NSAIDs are not reversed by the addition of
prostaglandins, or seem to occur at tissue concentrations lower
than those required for COX inhibition [44]. It is plausible that
NSAIDs differ in their ability to induce these COX-independent
effects, which may explain some of the differences observed in this
study.
In conclusion, we found that use of propionates was associated
with a small reduction in prostate cancer risk. There was no clear
evidence of dose-response or duration-response relationships with
any of the examined NSAID classes. Further studies are needed to
confirm the observed associations, and to address important
unanswered questions about the specific NSAIDs with the largest
benefits, and the optimal dose and duration of use required for
maximum benefits [46]. Compared to other novel chemopreven-
tive agents, the toxicity profiles of the classic NSAIDs are generally
well understood [1]. However, any potential benefits of NSAID
use would have to be carefully weighed against the risks associated
with their regular use [47].
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